Physician profile
Michael A Mann
NPI 1972582609
$1,882.53
in general payments reported to CMS, 2019-2025
23 companies · $916 in 2025
The $916 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $124 · 2023: $560 · 2024: $283 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $369.18 | 2023-2025 | |
| Genzyme Corporation | $177.20 | 2023-2025 | |
| Abbvie INC. | $144.11 | 2022-2025 | |
| Leo Pharma INC. | $118.75 | 2022-2025 | Adbry, Anzupgo |
| Organon LLC | $109.24 | 2025 | Vtama |
| Amgen INC. | $107.44 | 2022-2025 | Otezla |
| Lilly USA, LLC | $103.90 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $100.55 | 2022-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $87.72 | 2023-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $71.09 | 2025 | Tremfya |
| Pfizer INC. | $68.59 | 2022-2023 | |
| Incyte Corporation | $63.75 | 2023-2024 | Opzelura |
| Ucb, INC. | $59.78 | 2023-2024 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $52.75 | 2022-2024 | Sotyktu |
| Cipher Pharmaceuticals US LLC | $52.09 | 2025 | Spinosad, Natroba |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $36.29 | 2024 | Vtama |
| Botanix Sb INC | $27.63 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $24.82 | 2025 | Valchlor |
| Sun Pharmaceutical Industries INC. | $24.59 | 2023 | Winlevi, Absorica Ld |
| Sebela Pharmaceuticals INC. | $23.68 | 2023 | Pramosone, Naftin |
| Mayne Pharma Commercial LLC | $21.26 | 2023 | |
| Arcutis Biotherapeutics, INC. | $19.24 | 2025 | Zoryve |
| Biofrontera INC. | $18.88 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.